2月25日晚间，牧原股份（证券代码：002714.SZ）发布公告，拟变更公司名称。 具体来看，公司中文名称将由"牧原食品股份有限公司" 变更为 "牧原食品集团股份有限公司"；证券简称"牧原股份"和证券代码"002714"保持不 变。 | | 变更前 | 变更后 | | --- | --- | --- | | 公司名称(中文) | 牧原食品股份有限公司 | 牧原食品集团股份有限公司 | | 公司名称(英文) | MUYUAN FOODS CO., LTD. | MUYUAN FOODS GROUP CO., | | | | LTD. | 对于此次更名，牧原股份在公告中解释，此举是为顺应公司国际化发展战略，更好地发挥集团化优势，强化公司管理需求，提升公司整体运营效 率。 完成香港上市 海外布局加速 今年2月6日，牧原股份在香港联交所上市，成为国内生猪养殖行业首家实现"A+H"上市的企业。 根据公开信息，牧原股份本次全球发售H股基础发行规模为2.74亿股，最终确定发行价为每股39港元，募集资金净额约104.6亿港元。 牧原股份表示，本次港股发行最主要的目的是推进全球化战略，公司希望借助香港全球金融中心地位，打造国际 ...

Investment Rating - The report assigns an "Accumulate" rating to the company [1][6]. Core Insights - The report highlights the strong innovative research and development capabilities of the company, which is entering a harvest period for innovative drugs while establishing an international business development ecosystem with several significant collaborations [2][10]. - The company is expected to achieve a compound annual growth rate (CAGR) in earnings per share (EPS) of 48% from 2025 to 2027, with a target price set at HKD 16.58 [10]. Financial Summary - Total revenue is projected to be RMB 31,450.11 million in 2023, with a slight increase of 1.7% year-on-year. However, a decline of 7.8% is expected in 2024, followed by a gradual recovery in subsequent years [4][11]. - Gross profit is forecasted to be RMB 22,177 million in 2023, with net profit expected to be RMB 5,873 million, reflecting a decrease of 3.6% [4][11]. - The price-to-earnings (P/E) ratio is projected to be 18.26 in 2023, increasing to 24.78 in 2024 before declining to 16.80 in 2025 [4][11]. Pipeline Overview - The company has a leading position in the oncology pipeline, with SYS6010 being the fastest progressing EGFR ADC globally, and multiple early-stage assets expected to report data in 2026 [10][14]. - In the weight loss and metabolic fields, the company has established a leading position domestically, with a strategic collaboration with AstraZeneca to develop innovative long-acting peptide drugs [10][24]. - The company has secured a total deal value of USD 18.5 billion from collaborations, including upfront payments and potential milestone payments [10][24]. Clinical Development - The report outlines several key clinical trials, including SYS6010, which is in Phase III for EGFRm NSCLC, and various other assets in different stages of development [18][20]. - The company is actively recruiting for multiple trials, with significant data expected to be released in 2026 [18][20]. Market Position - The company is positioned as a leader in the domestic market for small nucleic acid technology, with a strong pipeline in siRNA [10][24]. - The report emphasizes the company's competitive edge in the next-generation weight loss drugs and cardiovascular metabolic therapies, supported by strategic partnerships with multinational corporations [10][24].

Investment Rating - The report assigns an "Accumulate" rating to the company [1][6]. Core Insights - The report highlights the strong innovation and R&D capabilities of the company, which is entering a harvest period for innovative drugs and has established an international business development ecosystem with several significant licensing agreements [2][10]. - The company is expected to achieve a significant increase in EPS from 0.37 in 2024 to 0.75 in 2025, with a projected growth rate of 48% [10]. - The target price for the company is set at 16.58 HKD, reflecting a favorable valuation based on comparable company analysis [10]. Financial Summary - Total revenue is projected to be 31,450.11 million RMB in 2023, with a slight increase of 1.7% [4]. - Net profit is expected to decrease by 3.6% in 2023, followed by a significant recovery of 47.5% in 2025 [4]. - The company’s PE ratio is forecasted to decrease from 18.26 in 2023 to 12.34 in 2026, indicating an improving valuation over time [4]. Pipeline Overview - The company has a leading position in the oncology pipeline, particularly with SYS6010, which is the fastest progressing EGFR ADC globally, with multiple early-stage assets expected to report data in 2026 [10][16]. - In the weight loss and metabolic areas, the company has established a leading position domestically and has signed a strategic collaboration with AstraZeneca for the development of innovative long-acting peptide drugs [10][24]. - The company has a robust pipeline in the small nucleic acid technology sector, positioning it as a leader in the domestic siRNA market [10][24]. Business Development and International Strategy - The company is making steady progress in its international strategy, with ongoing collaborations with AstraZeneca and other multinational corporations, reflecting its competitive edge in innovative drug development [10][24]. - The company is expected to continue achieving external licensing agreements, with over 20 innovative drug assets entering clinical stages annually [10][24].

2月25日晚，国内生猪养殖龙头牧原食品股份有限公司（002714.SZ/02714.HK，下称"牧原股份"）发布公告，公司 董事会审议通过更名议案，拟将全称变更为牧原食品集团股份有限公司，证券简称与代码保持不变。此次更名被 视为公司顺应国际化战略、强化集团化运营的重要信号。 牧原股份表示，更名旨在顺应国际化发展战略、更好发挥集团化优势、强化管理协同、提升整体运营效率。随着 公司完成A+H两地上市、业务版图持续扩张，原有名称已难以匹配其全球化布局与多板块协同的运营架构，加 入"集团"表述更贴合当前治理结构与发展阶段。 此次更名不涉及主营业务调整、证券简称与代码变更，对公司现有债权债务、合同履行及经营活动不构成影响。 截至2月26日午间收盘，牧原股份报45.31元，上涨1.16%，总市值约2600亿元。 作为全球生猪养殖龙头，牧原股份近年持续推进全产业链与全球化布局，在育种、饲料、养殖、屠宰、食品加工 等环节形成闭环，并通过智能化、集约化模式构筑成本壁垒。 牧原股份此前发布的2025年度业绩预告显示，预计归母净利润147亿元至157亿元，同比下降12.20%至17.79%；预 计扣非净利润151亿元至161亿元， ...

当下AI发展日新月异，技术迭代不断提速，应用场景加速落地。日前，汇川技术董事长朱兴明表示， 汇川技术坚定推进"AI+"战略，积极探索2026年将AI业务打造成公司营利组织的可行路径。 朱兴明表示，未来的商业竞争中，无论布局哪条业务线，若不能深入场景、重构场景、创造场景，创新 就很难真正落地。这一趋势在To C领域已表现得极为突出，如今也正快速向To B领域蔓延。汇川技术这 类企业，本就是吃"百家饭"的，必须反应敏捷，与众多客户同频共振。 ● 本报记者 张兴旺 未雨绸缪系统性变革 汇川技术成立于2003年，是国内工业自动化控制领域的佼佼者，聚焦工业领域的自动化、数字化、智能 化，专注于工业自动化控制产品的研发、生产和销售。瑞银研报称，汇川技术是中国工业自动化行业的 领先公司，拥有全面的产品组合、解决方案能力和快速响应的服务。汇川技术利用工业领域的自动化和 数字化的核心技术，致力于服务高端设备制造商。 汇川技术预计2025年营收为429.68亿元-466.72亿元，同比增长16%-26%；归属于上市公司股东的净利润 为49.71亿元-54亿元，同比增长16%-26%。汇川技术表示，报告期内，公司营收取得较好增长， ...

截至2025年9月末，现金及等价物为3.91亿元，现金流状况稳健。 核心产品包括云母硬质材料、柔质材料、发热组件、热管理安全组件及衍生品，适用于新能源汽车、轨道交 通、航天船舶、特种电缆和智能家电等高端领域，提供电绝缘与热绝缘一体化解决方案，在制造业供应链中 占据关键位置。 2025年，公司通过并购扩展业务，进入机器人精密结构件领域。以1.65亿元收购狄兹精密41.2%股权，并追加 8000万元增资，最终持有51%股权并取得控制权。此次交易完善高端制造布局，并为业绩增长提供新动力。 财务指标显示，公司保持稳定增长。2023年和2024年营收分别为8亿元和11.35亿元，毛利分别为2.82亿元和 3.63亿元，净利润分别为1.72亿元和2.3亿元。2025年前三季度营收达9.60亿元，同比增长18.7%；毛利3.27亿 元，净利润2.04亿元。 浙江荣泰冲刺H股，码绝缘材料与精密结构件，拓宽国际化布局 据新浪财经报道，2026年1月，浙江荣泰电工器材股份有限公司向香港交易所提交上市申请，拟发行H股并在 主板挂牌，中信证券为独家保荐人。 此举将使公司进入A+H双资本市场阶段，利用国际融资渠道支持海外产能扩展和新业 ...

Core Viewpoint - The company plans to change its name to align with its internationalization strategy and enhance management, without involving any manipulation of stock prices [1] Group 1 - The board of directors approved a proposal to change the company's name on February 25, pending shareholder approval [1] - The Chinese name will change from "牧原食品股份有限公司" to "牧原食品集团股份有限公司," and the English name will change from "MUYUAN FOODS CO., LTD." to "MUYUAN FOODS GROUP CO., LTD." [1] - The name change requires approval from the market supervision bureau for final registration [1]

Company Project Progress - The collaboration project with the Gates Foundation has advanced, with the development of ultrasound equipment's gestational age and fetal position functions completed and now entering clinical validation and confirmation stages. Three new automatic measurement functions in obstetrics are in the clinical data collection and performance optimization phase, which may impact the product launch timeline [1] Project Development - The overseas capacity layout has deepened, with a new facility in the U.S. (covering 1,940 square meters) fully certified as of July 2025. The company plans to flexibly arrange domestic and overseas capacity based on order demand, which is expected to enhance supply chain resilience in the long term. The main structure of the second-phase industrial building has been capped, and internal decoration is underway, with production capacity expected to ramp up in phases after launch [2] Strategic Advancement - The internationalization strategy is being continuously promoted, with plans to drive growth in international markets through product iteration upgrades and expanding local construction overseas, particularly in patient monitoring and ultrasound imaging businesses [3]

长江商报消息 ●长江商报记者 徐阳 又一家A股上市公司拟赴港上市，冲刺A+H。 华明装备在近期的投资者关系活动中表示，截至2025年三季度，公司海外收入占比超30%，其中直接与 间接出口比例接近1:1，直接出口略高；间接出口增速远快于直接出口，直接出口毛利率仍高于间接出 口，但直接出口与间接出口的毛利率正逐渐接近。 二级市场方面，赴港上市公告发布次日，即2月13日，华明装备股价下跌3.26%，报收33.83元/股。总体 来看，华明装备股价仍处于高位，仅从2025年年初至2026年2月13日期间累计涨幅就超过100%。 股价上涨背后是，华明装备回购、分红不断。公司2026年2月4日披露关于回购公司股份进展的公告，公 司于2025年年初启动了股份回购计划，截至2026年1月31日已累计回购股份金额达2.21亿元（不含交易 费用）。 根据华明装备2023—2025年股东回报规划，公司承诺每年现金分红比例不低于可分配利润的60%。2023 年、2024年均已超额兑现承诺。公司2025年前三季度累计已派发现金红利3.58亿元，稳步兑现年度承 诺。 日前，变压器分接开关龙头企业华明装备（002270.SZ）公告称，拟筹划 ...

牧原股份近日登陆港交所，成为国内生猪养殖行业首家实现"A+H"双上市的企业。作为全球出栏量最大 的养猪企业，牧原股份借此为其国际化战略搭建了投融资渠道，但也带来新的经营课题。 不过双线并行也有许多风险需要注意。中国企业资本联盟副理事长柏文喜提示，"A+H"布局需重点警惕 估值落差、监管差异、治理整合三类风险。港股机构投资者占比高，对生猪养殖等强周期、重资产、利 润波动大的行业估值显著低于A股，可能会导致H股股价表现低于预期，影响融资效率。两地在会计准 则、信息披露等监管规则上也存在差异，企业需调整财务与治理体系以适配港股要求，防范因合规问题 导致的股价波动或罚款。此外，国际投资者更看重公司治理与长期战略，牧原作为A股企业，过去更注 重规模扩张，整合过程中可能出现理念冲突，影响决策效率。 多家投资机构入局 牧原股份H股发行引入了多家机构作为基石投资者，正大集团、丰益、中化香港、香港豫农国际、富达 基金、高毅、平安人寿保险、UBS AM等机构均在列，涵盖国际产业龙头、全球顶级资产管理机构等多 元主体。基石投资者合计认购金额约53.42亿港元，占全球发售股份的50%。 下一步，牧原股份不仅需要适配两地资本市场在监管 ...